Tango Therapeutics Appoints Experienced Biopharma CFO Sung Lee to Board of Directors
TNGX has more than doubled off its 52-week low of $1.03 on light trading volume (0.4× avg).
Summary
Tango Therapeutics appointed Sung H. Lee, an experienced biopharma finance executive, to its Board of Directors, enhancing the board's financial and strategic expertise.
Key Events · Executive and Board Changes · TNGX
-
Board Expansion and New Director
The Board of Directors increased its size to eight and appointed Sung H. Lee as a new independent Class I director, effective January 2, 2026.
-
Sung Lee's Extensive Experience
Mr. Lee brings over 20 years of finance leadership, currently serving as EVP and CFO at Cytokinetics, with prior CFO roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics, and 14 years at Gilead Sciences.
-
Director Compensation
Mr. Lee will receive a stock option to purchase 60,000 shares at an exercise price of $8.93, a restricted stock unit award for 10,000 shares, and an annual retainer of $40,000.
Analysis · TNGX · Life Sciences
The appointment of Sung H. Lee, a seasoned finance executive with over two decades of experience in the biopharmaceutical and technology sectors, significantly strengthens Tango Therapeutics' Board of Directors. His background as CFO at multiple biotech companies and his tenure at Gilead Sciences will be invaluable as Tango advances its lead program, vopimetostat, into registrational studies and scales its organization for late-stage clinical development. This move enhances the company's financial and strategic oversight.
At the time of this filing, TNGX was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.03 to $11.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.